PARP1 and hepatocellular carcinoma: Therefore, OGE could serve as an effective regimen for targeting wild-type BRCA1, providing an opportunity for combination with PARP inhibitors, such as olaparib, niraparib, and rucaparib, to improve therapeutic outcomes in patients with HCC.